Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Clinician and Patient Factors Influencing Treatment Decisions in Front-Line Chronic Lymphocytic Leukemia: A Qualitative Research Study

Michael Wallington, Xavier Guillaume, Emily Mulvihill, Graceanne R Wayser, Vandana Kaul, Claire Graziani-Taugeron, Mina Shahkarami, Kellie J. Ryan

Blood (2022) 140 (Supplement 1): 10810–10811.

https://doi.org/10.1182/blood-2022-165766

Published: 2022

Journal Articles

Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia

Lindsey E. Roeker, Maral DerSarkissian, Kellie J. Ryan, Yan Chen, Svea K. Wahlstrom, Shweta Hakre, Louise Yu, Helen Guo, Anthony R. Mato

Blood (2022) 140 (Supplement 1): 4156–4158.

https://doi.org/10.1182/blood-2022-167213

Published: 2022

Journal Articles

Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lindsey E. Roeker, Yi Han, Kellie J. Ryan, Anna Teschemaker, Anthony R. Mato

Blood (2022) 140 (Supplement 1): 7025–7027.

https://doi.org/10.1182/blood-2022-163534

Published: 2022

Journal Articles

Shift in First-Line Therapies for United States Veterans Health Administration (VHA) Patients with Chronic Lymphocytic Leukemia (CLL) from 2014 to 2021

Kana Tai Lucero, Christopher R. Frei, Kellie J. Ryan, Obiageri O. Obodozie-Ofoegbu, Amanda M. Moore, Chengwen Teng, Xavier Jones, Zohra Nooruddin

Blood (2022) 140 (Supplement 1): 9915–9916.

https://doi.org/10.1182/blood-2022-163797

Published: 2022

Journal Articles

Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax

Hetalkumari Patel, Svea K. Wahlstrom, Maral DerSarkissian, Colin Kunzweiler, Felicia Castriota, Rose Chang, Hoi Ching Cheung, Yuqian Gu, Helen Guo, Mei Sheng Duh, Kellie J. Ryan

Blood (2021) 138 (Supplement 1): 2999.

https://doi.org/10.1182/blood-2021-147449

Published: 2021

Journal Articles

Uptake of Novel Agents (NAs) As First-Line Treatments for Black and White Patients with Chronic Lymphocytic Leukemia (CLL) in the Veterans Health Administration (VHA): A Retrospective Cohort Study

Kana Tai Lucero, Obiageri O. Obodozie-Ofoegbu, Zohra Nooruddin, Alyssa Castillo, Amanda M. Moore, Kellie J. Ryan, Xavier Jones, Christopher R. Frei

Blood (2021) 138 (Supplement 1): 340.

https://doi.org/10.1182/blood-2021-146860

Published: 2021

Journal Articles

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Geoffrey L Uy, MD, Laura F. Newell, MD, Tara Lin, MD, Stuart L. Goldberg, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-136882

Published: 2020

Journal Articles

Final Primary Results from the Defifrance Registry Study: Effectiveness and Safety of Defibrotide in the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation

Mohamad Mohty, MD PhD, Ibrahim Yakoub-Agha, Myriam Labopin, MD, Didier Blaise, MD, Delphine Lebon, MD, Virginie Gandemer, MD PhD, Sébastien Maury, Cecile Renard, Charlotte Jubert, Robert J. Ryan, Virginie Bouvatier, Jean-Hugues Dalle, MD PhD, Regis Peffault De Latour, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-136685

Published: 2020

Journal Articles

Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Tara Lin, MD, Geoffrey L Uy, MD, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet, MD

Blood (2020) 136 (Supplement 1): 55–56.

https://doi.org/10.1182/blood-2020-136871

Published: 2020

Journal Articles

Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Analysis of a Multinational, Prospective, Observational Registry Study

Franco Locatelli, MD PhD, Maura Faraci, Ibrahim Yakoub-Agha, Stephane Girault, Kate Wheeler, Robert J. Ryan, Raj Hanvesakul, Mohamad Mohty, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136670

Published: 2020

Journal Articles

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)

R. Coleman Lindsley, MD PhD, Christopher J. Gibson, MD, H. Moses Murdock, BS, Richard M. Stone, MD, Jorge E. Cortes, MD, Geoffrey L. Uy, MD, Tara L. Lin, MD, Ellen K. Ritchie, MD, Thomas Prebet, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 15.

https://doi.org/10.1182/blood-2019-124500

Published: 2019

Journal Articles

A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT)

Mohamad Mohty, MD PhD, Marta Lisa Battista, Didier Blaise, MD PhD, Elisabetta Calore, MD, Simone Cesaro, Adam Gassas, Natalia Maximova, Katia Perruccio, Cecile Renard, MD, Robert Wynn, Marco Zecca, Myriam Labopin, MD, Raj Hanvesakul, Robert J. Ryan, MS, Fabio Ciceri, MD, Sarah Lawson, MD

Blood (2019) 134 (Supplement_1): 1972.

https://doi.org/10.1182/blood-2019-123529

Published: 2019

Journal Articles

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Jeffrey E. Lancet, MD, David A. Rizzieri, MD, Gary J. Schiller, MD, Scott R. Solomon, MD, Laura F. Newell, MD, Harry P. Erba, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1313.

https://doi.org/10.1182/blood-2019-124383

Published: 2019

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

Tara L. Lin, MD, Daniel H. Ryan, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1316.

https://doi.org/10.1182/blood-2019-124552

Published: 2019

Journal Articles

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Jonathan E. Kolitz, MD, Daniel H. Ryan, MD, Laura F. Newell, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Gary J. Schiller, MD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3856.

https://doi.org/10.1182/blood-2019-124553

Published: 2019

Journal Articles

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Daniel H. Ryan, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Richard M. Stone, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3842.

https://doi.org/10.1182/blood-2019-124516

Published: 2019

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies

Blood (2017) 130 (Supplement 1): 2657.

https://doi.org/10.1182/blood.V130.Suppl_1.2657.2657

Published: 2017

Journal Articles

Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC)

Anuraag Kansal, Mark Du, Oscar Herrera-Restrepo, Robert Leipold, Robert J. Ryan, Arthur C. Louie, Karen Chung

Blood (2017) 130 (Supplement 1): 4674.

https://doi.org/10.1182/blood.V130.Suppl_1.4674.4674

Published: 2017

Journal Articles

Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Neuroblastoma: Final Data from the Defibrotide Expanded-Access Program

Stephan A Grupp, MD PhD, Brandon Triplett, MD, Araz Marachelian, MD, Sonata Jodele, MD, Robert J. Ryan, Robin L. Hume, MS, William Martin Tappe, MD, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 4549.

https://doi.org/10.1182/blood.V130.Suppl_1.4549.4549

Published: 2017

Journal Articles

Pooled Analysis of Day +100 Survival for Defibrotide-Treated Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) and Ventilator or Dialysis Dependence Following Hematopoietic Stem Cell Transplantation (HSCT)

Paul G Richardson, MD, Angela R. Smith, MD MS, Nancy A. Kernan, MD, Joseph H. Antin, MD, Leslie Lehmann, MD, Robert J. Ryan, Robin L. Hume, MS, William Martin Tappe, MD, Stephan A Grupp, MD PhD

Blood (2017) 130 (Supplement 1): 1946.

https://doi.org/10.1182/blood.V130.Suppl_1.1946.1946

Published: 2017

NARROW

Clinician and Patient Factors Influencing Treatment Decisions in Front-Line Chronic Lymphocytic Leukemia: A Qualitative Research Study

Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia

Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Shift in First-Line Therapies for United States Veterans Health Administration (VHA) Patients with Chronic Lymphocytic Leukemia (CLL) from 2014 to 2021

Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax

Uptake of Novel Agents (NAs) As First-Line Treatments for Black and White Patients with Chronic Lymphocytic Leukemia (CLL) in the Veterans Health Administration (VHA): A Retrospective Cohort Study

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Final Primary Results from the Defifrance Registry Study: Effectiveness and Safety of Defibrotide in the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation

Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)

Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Analysis of a Multinational, Prospective, Observational Registry Study

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)

A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT)

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies

Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC)

Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Neuroblastoma: Final Data from the Defibrotide Expanded-Access Program

Pooled Analysis of Day +100 Survival for Defibrotide-Treated Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) and Ventilator or Dialysis Dependence Following Hematopoietic Stem Cell Transplantation (HSCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only